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1. Introduction 
The Swiss Childhood Cancer Registry (SCCR) is the national population-based cancer 
registry for children and adolescents in Switzerland. New cancer diagnoses, clinical 
information, details on treatment and long-term follow-up (survival, second primary 
neoplasms and late effects) have been registered in the SCCR since 1976. With many 
associated research projects and through close collaboration with clinicians it contributes to 
understanding the causes of cancer in children, improving follow-up care and reducing late 
effects. 
The SCCR is located at the Institute of Social and Preventive Medicine (ISPM) at the 
University of Bern. It is operated jointly by the Swiss Paediatric Oncology Group (SPOG) and 
the University of Bern. All Swiss paediatric haematology-oncology centres report newly 
diagnosed cases to the registry and send annual updates on clinical follow-up. The SCCR 
began to systematically collect data from other sources in 2007, including the cantonal 
cancer registries, other hospitals, pathology laboratories and the Swiss Federal Statistical 
Office (SFSO). As of 31 December 2011, data from 8712 patients have been registered.  
The SCCR is authorized to collect non-anonymised data by the Federal Commission of 
Experts for Professional Secrecy in Medical Research (Eidgenössische Expertenkommission 
für das Berufsgeheimnis in der medizinischen Forschung). 
The SCCR is an associated member of the National Institute for Cancer Epidemiology and 
Registration (NICER), of the European Network of Cancer Registries (ENCR) and of the 
International Association of Cancer Registries (IACR), and collaborates with childhood 
cancer registries throughout Europe. 
This fifth annual report covers the routine analyses of all children diagnosed between             
1 January 1976, and 31 December 2011. Activities and projects of the SCCR are described 
for the years 2011 and 2012. This report contains: 
 An overview of the organisation and team of the SCCR, SPOG and the participating 
paediatric haematology-oncology centres (Chapter 2) 
 A summary of the data collected in the registry up to 31 December 2011 (Chapter 3) 
 A list of current research projects of the SCCR (Chapter 4) 
 A list of publications (Chapter 5) 
 Abbreviations and appendix (Chapters 6 & 7) 
Our website (www.childhoodcancerregistry.ch) contains further information, including past 
annual reports and scientific publications. 
We would like to thank all the children and their families, and all adolescent and adult 
childhood cancer survivors, for allowing us to collect their data. We also thank the 
physicians and data managers of the Swiss Paediatric Oncology Group for their excellent 
collaboration. Our thanks also go to the cantonal cancer registries, the National Institute for 
Cancer Epidemiology and Registration (NICER), the Swiss Federal Statistical Office (SFSO), 
the Federal Office of Public Health (FOPH) and the pathology laboratories for their 
cooperation. Finally, we thank our supporters for their generous contributions. 
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2. Organisation of the Swiss Childhood Cancer Registry 
The Swiss Childhood Cancer Registry (SCCR) is a member of the Swiss Paediatric Oncology 
Group (SPOG) and is organised as a joint operation of the Institute of Social and Preventive 
Medicine (ISPM) at the University of Bern and the SPOG. 
2.1 Institute of Social and Preventive Medicine (ISPM), University of 
Bern 
Finkenhubelweg 11, 3012 Bern 
Tel.: +41 (0)31 631 56 70 / +41 (0)31 631 38 99 
Fax: +41 (0)31 631 36 48 
www.childhoodcancerregistry.ch 
Direction 
Claudia Kuehni, Prof MD Head of SCCR kuehni@ispm.unibe.ch 
Gisela Michel, PhD Vice head of SCCR michel@ispm.unibe.ch 
   
Swiss Childhood Cancer Registry 
Vera Mitter, MSc Project coordinator vmitter@ispm.unibe.ch 
Elisabeth Kiraly, MD Diagnostic coding kiraly@ispm.unibe.ch 
Marlen Spring Data manager mspring@ispm.unibe.ch 
Katharina Flandera Administration kflandera@ispm.unibe.ch 
   
Trust Centre  
Christiana Krenger Data manager ckrenger@ispm.unibe.ch 
Janine Eichenberger Data manager jeichenberger@ispm.unibe.ch 
   
Informatics and database support  
Priska Wölfli Database support pwoelfli@ispm.unibe.ch 
Malcolm Sturdy  Database support sturdy@ispm.unibe.ch 
   
Research projects   
Ben Spycher, PhD Research fellow, Project manager bspycher@ispm.unibe.ch 
Eva-Maria Hau, MD Research fellow, Project manager ehau@ispm.unibe.ch 
Corina Rüegg, PhD Research fellow, Project manager crueegg@ispm.unibe.ch 
Grit Sommer, PhD Research fellow, Project manager gsommer@ispm.unibe.ch 
Rahel Kuonen, MSc Research fellow rkuonen@ispm.unibe.ch 
Laura Wengenroth, MSc PhD student lwengenroth@ispm.unibe.ch 
Micòl Gianinazzi, MA/BSc PhD student mgianinazzi@ispm.unibe.ch 
Stefan Essig, MD PhD student sessig@ispm.unibe.ch 
Judith Lupatsch, MSc PhD student jlupatsch@ispm.unibe.ch 
Matthias Schindler, MSc PhD student mschindler@ispm.unibe.ch 
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2.2 Swiss Paediatric Oncology Group (SPOG) 
SPOG Office  
Effingerstrasse 40, 3008 Bern 
Tel.: +41 (0)31 389 91 89  
Fax: +41 (0)31 389 92 00  
 
SPOG Executive Board   
Felix Niggli, Prof MD President felix.niggli@kispi.uzh.ch 
Heinz Hengartner, MD Vice president heinz.hengartner@kispisg.ch 
Maja Beck Popovic, PD MD Secretary maja.beck-popovic@chuv.ch 
Nicolas von der Weid, Prof MD Past president nicolas.vonderweid@ukbb.ch 
 
SPOG Office in Bern   
Isabelle Lamontagne-Müller, MSc Managing director isabelle.lamontagne@spog.ch 
Stefanie Lerch, PhD Quality assurance stefanie.lerch@spog.ch 
Martina Peluso, MSc Regulatory affairs  martina.peluso@spog.ch 
Olivier Leroy, PhD Regulatory affairs olivier.leroy@spog.ch 
Marianne Peer Director’s assistant marianne.peer@spog.ch 
 
Participating centres (paediatric haematology-oncology) 
 Head of Division Local Data Manager 
Aarau (Kinderklinik, Kantonsspital Aarau) R. Angst, MD C. Anderegg, MSc 
Basel (Universitätskinderspital beider 
Basel [UKBB]) 
N. von der Weid, Prof MD V. Stahel 
Bern (Universitätsklinik für 
Kinderheilkunde, Inselspital) 
K. Leibundgut, Prof MD F. Julmy  
N. Beusch 
Genève (Hôpital des Enfants, Hôpitaux 
Universitaires de Genève [HUG]) 
M. Ansari, MD 
 
G. Perrenoud, MSc 
Lausanne (Service de Pédiatrie, Centre 
Hospitalier Universitaire Vaudois [CHUV]) 
M. Beck Popovic, PD MD R.-E. Garcia, MD 
Bellinzona (Reparto di Pediatria, 
Ospedale S. Giovanni, Bellinzona) 
P. Brazzola, MD P. Brazzola, MD 
Luzern (Kinderspital, Kantonsspital 
Luzern) 
J. Rischewski, PD MD N. Lanz 
St.Gallen (Ostschweizer Kinderspital) J. Greiner-Lang, MD F. Hochreutener 
Zürich (Kinderspital, Universitäts-
Kinderklinik, Zürich) 
F. Niggli, Prof MD 
M. Grotzer, Prof MD 
H. Markiewicz 
A. Reinberger 
R. Siegenthaler 
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2.3 General information 
Aims  
The Swiss Childhood Cancer Registry collects information on the diagnosis, treatment and 
follow-up of cancer in children and adolescents in Switzerland and provides data for 
national and international statistics and research projects: 
 To collect representative, population-based data on cancer in children and adolescents 
in Switzerland (cancer incidence, prevalence, time trends, regional distribution and 
survival rates). 
 To document diagnostic evaluations, treatment and participation in clinical trials. 
 To describe short term and long term prognosis (mortality, morbidity and quality of life) 
after cancer in childhood and adolescence – (remission, relapses, survival, late effects 
and quality of life). 
 To provide a research platform for clinical, epidemiological and basic research 
 
It thus contributes to: 
 Continuous improvement of treatment 
 The planning of health services  
 Identifying possible late effects of therapy, with the aim to diagnose and treat them 
early and prevent them in future  
 Research into the aetiology of cancer in children and adolescents.  
 
Inclusion criteria 
The SCCR registers all children and adolescents aged 0 to 20 years resident, or treated in 
Switzerland, diagnosed with: 
 Acute and chronic leukaemias, including myelodysplastic syndrome 
 Lymphomas 
 Malignant solid tumours 
 Central nervous system tumours (CNS), malignant and benign tumours  
 Langerhans cell histiocytosis (LCH)  
Children and adolescents who are not Swiss residents but are diagnosed or treated in 
Switzerland are registered, but they are excluded from analyses of incidence and survival. 
 
  
 10 
Sources of data 
Data on children and adolescents with cancer are collected from several sources, including:  
 The nine Swiss centres for paediatric oncology and haematology (Chapter 2.2) 
 Other hospitals 
 Clinical and epidemiological registries (e.g. brain tumour registry, bone tumour registry, 
Swiss growth registry etc.) 
 Cantonal cancer registries, organised in the National Institute for Cancer Epidemiology 
and Registration (NICER) 
 The Swiss Federal Statistical Office (SFSO; Swiss mortality statistics) 
 Pathology laboratories  
Most children (95%) are reported by one of the nine Swiss centres for paediatric oncology 
and haematology. Local data managers complete forms for all newly diagnosed patients. 
Basic information on diagnosis is later completed with information on treatments, 
remissions, relapses, transplantations and late outcomes. These forms are sent to the SCCR 
and information is entered into the database. Important medical documents (e.g. pathology 
reports) are scanned and stored electronically using a pseudonym. Paper copies are 
destroyed. Information on Swiss residency is validated through municipal population 
registers. 
Data on follow-up care in paediatric oncology and haematology centre is extracted annually 
from patients’ hospital records for the first five to ten years after diagnosis (page 18, 
Chapter 3.2). To assess outcomes after the children have left the clinic, patients are directly 
contacted with a questionnaire (Chapter 4: Swiss Childhood Cancer Survivor Study and 
Follow-up care after childhood and young adult cancer) and data is linked to mortality 
records (SFSO) and to records from cantonal cancer registries (Chapter 4: Mortality and 
second primary cancers after cancer in childhood and adolescence). For children not treated 
in a paediatric oncology and haematology centre, clinical follow-up from hospitals is often 
not available, but long-term epidemiological follow-up is done via questionnaires and by 
assessment of second primary neoplasms and mortality as for the other patients (page 18, 
Chapter 3.2). 
Clinical database 
The current SCCR database was set up in 2007. The following information is collected: 
 Tumour diagnosis, date of diagnosis, morphology, topography, stage, metastases 
 Other diagnoses (relevant pre-existing conditions) 
 Relevant laboratory and clinical data 
 Treatment (clinical trial participation, chemotherapy, radiotherapy, surgical intervention, 
bone marrow transplantation) and treatment centres involved 
 Follow-up data (changes of treatment, remissions, relapses, survival/death and cause of 
death) 
 Late adverse outcomes (e.g. cardiovascular diseases, second primary neoplasms and 
endocrine disorders)  
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Trust centre 
Since 2010, personal information (name and address) is stored in a separate database in the 
trust centre. The trust centre validates addresses, residence status, nationality, and vital 
status via municipal population registers. This personal information is strictly separated from 
clinical information contained in the SCCR database. The following data is collected:  
 Patient names, address at time of diagnosis, address history and current address 
 Date of birth, sex, first language 
 Residency and nationality at time of diagnosis 
 Vital status and date of death 
 Parental professions, parental dates of birth 
 
Tumour coding 
All tumours are coded according to the following international classification systems (see 
appendix):  
 International Classification of Childhood Cancer, third edition (ICCC-3)1 
 International Classification of Diseases for Oncology, third edition (ICD-O-3)2 
 International Classification of Diseases and Related Health Problems, tenth revision (ICD-10)3 
In the annual report, the main diagnostic groups of the ICCC-3 are used:  
I.  Leukaemias, myeloproliferative diseases, and myelodysplastic diseases 
II.  Lymphomas and reticuloendothelial neoplasms 
III.  CNS and miscellaneous intracranial and intraspinal neoplasms 
IV.  Neuroblastoma and other peripheral nervous cell tumours 
V.  Retinoblastoma 
VI. Renal tumours 
VII. Hepatic tumours 
VIII. Malignant bone tumours 
IX.  Soft tissue and other extraosseous sarcomas 
X. Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 
XI.  Other malignant epithelial neoplasms and malignant melanomas 
XII.  Other specified and unspecified malignant neoplasms  
Langerhans cell histiocytosis (LCH), which is not included in ICCC-3, is reported 
separately. 
                                               
1 Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer 2005; 103:1457-1467. 
2 World Health Organization. International Statistical Classification of Diseases for Oncology - Third Edition (ICD-O-3). Geneva: World Health Organization; 2000. 
3 World Health Organization. International Statistical Classification of Diseases and Related Health Problems - Tenth Revision. Geneva: World Health Organization; 1993. 
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Data protection 
In 2004, the SCCR received a special authorization (Sonderbewilligung) from the Swiss 
Federal Commission of Experts for Professional Secrecy in Medical Research. In June 2007, 
this was followed by a general authorization (Registerbewilligung) permitting collection of 
cancer data from children and adolescents throughout Switzerland by obtaining written, 
oral or silent consent. A copy of the document provided by the expert commission can be 
downloaded from our homepage,4 together with explanations in French and German. At 
time of diagnosis, all patients and their parents are informed about the childhood cancer 
registry by the treating physician. The families have the right to prevent transfer of non-
anonymised data to the registry (veto power/possibility to opt out). Records of these 
patients are fully anonymised. Patients are also informed about the registry in hospital 
brochures, on hospital notice boards, and by patient organisations. All data in the SCCR is 
kept strictly confidential. Personal information (names, addresses) is stored in a separate 
database (Trust centre), separated from clinical information. 
Data protection measures of the SCCR were examined by the Federal Data Protection and 
Information Commissioner and the cantonal data protection officer of Bern in 2010. In 
collaboration with these authorities, data collection and data storage modalities were 
revised and refined. The new procedures were approved by the Federal Commission of 
Experts for Professional Secrecy in Medical Research in 2010. 
 
  
                                               
4 http://www.childhoodcancerregistry.ch/index.php?id=2451 
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Funding 
The SCCR thanks the following supporters for their financial contributions towards daily 
running and continuous development of the registry. Supporters of scientific research 
projects are listed in Table 7, page 30. 
 
Main fund givers 2011/2012 
 Schweizerische Konferenz der kantonalen Gesundheitsdirektoren und –direktorinnen 
(GDK) 
 Kinderkrebshilfe Schweiz  
 Schweizerische Pädiatrische Onkologie Gruppe (SPOG)  
 Stiftung für krebskranke Kinder Regio Basiliensis  
 Interpharma AG  
 AXA-Winterthur  
 
Other fund givers 2011/2012 
 Novartis  
 GlaxoSmithKline  
 Takeda Pharma  
 Celgene  
 CSL Behring  
 Bayer AG Schweiz  
 Prosperita, Stiftung für berufliche Vorsorge 
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3. Routine Analyses  
Overview 
The SCCR registers all tumours diagnosed and treated in Switzerland, classified according to 
the ICCC-3 and Langerhans cell histiocytosis (LCH) in patients aged 0 to 20 years at time of 
diagnosis. This annual report covers the time period from 1 January 1976 until 31 December 
2011. To calculate incidence we count the number of primary neoplasms (cases), which is 
slightly higher than the number of patients. Patients with more than one primary tumour 
diagnosed before age 20 years are counted separately for each new tumour.  
The section on routine analyses includes three chapters: 
Chapter 3.1 presents data on all cases registered in the SCCR. This includes cases resident 
in Switzerland or abroad, who are diagnosed or treated in Switzerland.  
Chapter 3.2 presents data on cases resident in Switzerland, aged 0 to 14 years at diagnosis. 
This is the age group usually covered in international publications, therefore tables and 
figures can be directly compared with data from other countries. Registration in Switzerland 
is more than 95% complete for this age range, allowing calculation of incidence and 
survival. 
Chapter 3.3 presents data on cases resident in Switzerland, aged 15 to 20 years at 
diagnosis. The SCCR is striving to improve completeness for this age group and is now 
presenting an overview table. Patients of this age group are treated in a large number and 
variety of clinics and therefore registration is less complete. Data comparison with cantonal 
cancer registries has improved completeness of data on adolescents for cantons with a 
cancer registry. Nevertheless, cancer registration in adolescents remains incomplete in the 
SCCR and is not population based. 
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3.1 All cases registered in the SCCR (N=8712) 
This chapter describes data from all cases diagnosed 1976-2011, resident in Switzerland or 
abroad, diagnosed or treated in Switzerland (N=8712). 
Up to 31 December 2011, a total of 8712 cases classifiable according to the ICCC-3, or 
Langerhans cell histiocytosis (LCH), have been registered in the SCCR. These tumours were 
diagnosed in 8608 patients. Among these, 8506 patients had only one primary neoplasm, 
100 patients had two primary neoplasms and 2 patients had three primary neoplasms at 
age 0-20.  
The SCCR started in 1976. Initially, it registered only patients aged 0 to 15 years who 
participated in clinical trials. Non-trial patients have been included since 1981, resulting in a 
significant increase in registered cases. In the early 1990s, the introduction of the first 
electronic database further increased case registration. Since then, annual registration has 
remained stable (Figure 1, Table 1). In the last five years (2007-2011), a total of 1266 
newly diagnosed cases were registered; among them 1139 in Swiss residents. 
Swiss residents account for 7728 (89%) of all cases and foreign residents for 984 (11%) 
cases (Table 2). Fifty-eight per cent (118/344) of retinoblastoma patients were foreign 
residents. This is due to the outstanding national and international reputation of the Jules 
Gonin Hospital in Lausanne, which is the national centre for retinoblastoma treatment but 
also attracts many patients from abroad. 
 
Figure 1 – Annual number of registered cases over time 
Swiss and foreign residents, age at diagnosis 0-14 years; period of diagnosis 1976-2011; all diagnoses (ICCC-3 
or Langerhans cell histiocytosis); N=6701 
 
  
0
50
100
150
200
250
300
1976 1980 1985 1990 1995 2000 2005 2010
Year of diagnosis 
Annual number of cases 
Total Swiss residents Foreign residents
 16 
Table 1 – Total number of cases registered, by period of diagnosis  
Swiss and foreign residents, age at diagnosis 0-20 years; period of diagnosis 1976-2011; all diagnoses (ICCC-3 
or Langerhans cell histiocytosis); N=8712 
 
 
All patients 
Age at diagnosis (years)  
Swiss residents 
Age at diagnosis (years)  
Foreign residents 
Age at diagnosis (years) 
Year of diagnosis 0-14 15-20  0-14 15-20  0-14 15-20 
1976-1981* 706 187  614 167  92 20 
1982-1986 791 248  696 223  95 25 
1987-1991 950 290  781 263  169 27 
1992-1996 1052 327  931 278  121 49 
1997-2001 1061 341  950 315  111 26 
2002-2006 1108 385  1018 353  90 32 
2007-2011 1033 233  923 216  110 17 
 
6701 2011  5913 1815  788 196 
* This period includes 6 years instead of 5. 
 
 
Table 2 - Total number of cases registered, by country of residence 
Swiss and foreign residents, age at diagnosis 0-20 years; period of diagnosis 1976-2011; all diagnoses (ICCC-3 
or Langerhans cell histiocytosis); N=8712 
 
   Age at diagnosis (years) 
 Total  0-14  15-20 
Country of residence n %  n %  n % 
1 Switzerland 7729 88.7  5913 88.3  1815 90.3 
2 Foreign countries 983 11.3  787 11.7  196 9.7 
a Europe 617 7.1  519 7.7  112 5.6 
 Neighbouring countries 383 4.4  314 4.7  69 3.4 
Austria 13 0.1  11 0.2  2 0.0 
France 126 1.4  91 1.4  35 1.5 
Germany 69 0.7  65 1.0  4 0.0 
Italy 155 1.8  129 1.9  26 1.3 
Liechtenstein 20 0.2  18 0.3  2 0.0 
 Other European countries 234 2.7  205 3.1  43 2.13 
b Middle East 46 0.5  23 0.3  9 0.4 
c North Africa 159 1.8  121 1.8  38 1.9 
d Other African countries 41 0.5  31 0.5  10 0.5 
e Other countries 120 1.4  94 1.4  27 1.3 
TOTAL 8712 100.0  6701 100.0  2011 100.0 
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3.2 Swiss residents aged 0-14 years at diagnosis (N=5913) 
This chapter relates only to cases aged 0-14 years and resident in Switzerland at diagnosis 
with a tumour coded according to ICCC-3 or a Langerhans cell histiocytosis. This age group 
is usually covered by international publications; tables and figures can be compared directly 
to data from other countries. By 31 December 2011, the SCCR contained data of 5913 
tumours diagnosed in this population.  
 
Diagnoses 
The International Classification of Childhood Cancer (ICCC-3) distinguishes 12 groups of 
cancers (Table 3). The most common are leukaemias (33% of all cancers), followed by 
tumours of the central nervous system (20%; especially brain tumours); and lymphomas 
(13%). Other cancers arise from embryonic tissue. These include neuroblastoma (7%) from 
primitive neural tissue, nephroblastoma (5%) from renal tissue, hepatoblastoma (1%) in the 
liver, retinoblastoma (3%) from cells of the retina, as well as germ cell tumours (3%). The 
latter may arise in the gonads (ovaries and testes), or in other sites, for example in the brain 
(intracranial germ cell tumours). In older children, malignant bone tumours (4%) and soft 
tissue sarcomas (7%), which arise from abnormal connective tissue, are occurring with 
increasing frequency. Sometimes children also develop melanomas and other rare tumours 
(3%). An intermediate position is hold by Langerhans cell histiocytosis (3%), which is not 
officially counted as malignant disease. But since they are treated similarly to cancer and in 
rare cases also may result in death, they are recorded in the Swiss Childhood Cancer 
Registry. The relative frequency of the different tumours varies significantly with age (Table 
3 and Figure 2).  
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Table 3 – Main diagnostic groups according to ICCC-3, by age at diagnosis 
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2011; all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=5913 
 
    Total Age at diagnosis (years) 
Diagnosis number <1yr 1-4yrs 5-9yrs 10-14yrs 
    n % n % n % n % n % 
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases 1925 32.6 76 13.0 921 44.4 541 34.1 387 23.2 
II Lymphomas and reticuloendothelial neoplasms 754 12.8 15 2.6 123 5.9 215 13.5 401 24.1 
III Central nervous system neoplasms 1162 19.7 61 10.4 336 16.2 433 27.3 332 19.9 
IV Neuroblastoma and other peripheral nervous cell tumours 397 6.7 176 30.1 176 8.5 30 1.9 15 0.9 
V Retinoblastoma 145 2.5 67 11.5 68 3.3 8 0.5 2 0.1 
VI Renal tumours 307 5.2 44 7.5 179 8.6 74 4.7 10 0.6 
VII Hepatic tumours 58 1.0 20 3.4 23 1.1 6 0.4 9 0.5 
VIII Malignant bone tumours 263 4.4 0 0.0 19 0.9 79 5.0 165 9.9 
IX Soft tissue and other extraosseous sarcomas 385 6.5 44 7.5 113 5.5 93 5.9 135 8.1 
X Germ cell tumours, trophoblastic tumours and neoplasms of gonads 157 2.7 29 5.0 40 1.9 23 1.4 65 3.9 
XI Other malignant epithelial neoplasms and malignant melanomas 155 2.6 10 1.7 8 0.4 35 2.2 102 6.1 
XII Other specified and unspecified malignant neoplasms 17 0.3 4 0.7 4 0.2 0 0.0 9 0.5 
 Langerhans cell histiocytosis 188 3.2 39 6.7 63 3.0 51 3.2 35 2.1 
  Total 5913 100.0 585 100.0 2073 100.0 1588 100.0 1667 100.0 
 
 
 
1
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Figure 2 – Main diagnostic groups according to ICCC3, by age at diagnosis (years) 
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2011; all diagnoses (ICCC-3 or 
Langerhans cell histiocytosis); N=5913 
The widths of the columns are proportional to the number of patients. 
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Follow-up information 
The SCCR collects follow-up information for patients in several ways:  
1. Clinical follow-up (Table 4) is any contact the patient has with the paediatric oncology 
and haematology centre. Annual clinical follow-up care in paediatric centres usually ends 5-
10 years after diagnosis, when the patient is officially discharged or referred to an adult 
oncology centre, or if the patient dies. Thirty–seven per cent of patients had a clinical 
follow-up in the past 5 years and another 16% had their last clinical follow-up 6-10 years 
ago. 
2. Long-term epidemiological follow-up for vital status, subsequent neoplasms and 
current health employs four complementary approaches: 
 Vital status and current address are updated by contacting municipal population 
registers. Vital status is known for most cases: among the 5864 patients, 1503 (25.6%) 
have died, and 252 (4.2%) were lost to follow-up, mostly because they moved abroad. 
For the other 4109 survivors, vital status has been updated within the last 5 years. 
 Causes of death are retrieved from Swiss mortality statistics by data linkage. 
 Second primary neoplasms are detected by regular comparison with cantonal 
(regional) cancer registries in Switzerland. 
 Morbidity and quality of life are assessed by postal questionnaires to survivors in the 
Swiss Childhood Cancer Survivor Study and Childhood Cancer Follow-up Study (SCCSS 
& CCFU, Chapter 4). 
 
Table 4 – Clinical Follow-up information available in the SCCR 
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2011; all diagnoses (ICCC-3 or 
Langerhans cell histiocytosis); N=5864 
 
Clinical follow-up at paediatric centre n % 
Last clinical follow-up 2007-2012 2167 37.0 
Last clinical follow-up 2002-2006 948 16.2 
Last clinical follow-up before 2002 1246 21.2 
Died 1503 25.6 
TOTAL  5864* 100.0 
*We counted patients instead of cases (patients with more than one primary neoplasm are only counted once). 
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Survival 
The following figures present data on the survival of patients registered in the SCCR. 
Figure 3 shows an actuarial curve presenting overall survival up to 35 years after diagnosis 
for patients diagnosed between 1976 and 2011, grouped in four periods. In total, 1503 
(25%) children have died. Ten-year survival increased from 60.5% in children diagnosed 
between 1976 and 1981, 70.3% in children diagnosed between 1982-1991, to 77.3% in 
children diagnosed between 1992 and 2001, and reached 82.7% in children diagnosed 
within the last decade.  
Figure 3 – Survival of patients in the SCCR, by period of diagnosis 
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2011; all diagnoses (ICCC-3 or 
Langerhans cell histiocytosis); N=5913; adjusted for sex, age at diagnosis and ICCC-3 groups 
 
 
 
 
Time since diagnosis (years) 
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Survival varied widely between diagnostic groups. Figure 4 presents survival by diagnostic 
group according to ICCC-3 in cases diagnosed between 1992 and 2011. Of these, 756 
(19.8%) have died. The following numbers describe five-year survival for each main 
diagnostic group: 82.6% for cases with leukaemias; 92.4% for those with lymphomas; 
71.7% for central nervous system neoplasms; 63.4% for neuroblastoma; 96.1% for 
retinoblastoma; 91.3% for renal tumours; 65.7% for hepatic tumours; 85.6% for 
malignant bone tumours; 74.0% for soft tissue sarcomas; 96.4% for germ cell tumours; 
and 100.0% in Langerhans cell histiocytosis. 
Figure 4 – Survival of patients by diagnostic groups according to ICCC-3 
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1992-2011; all diagnoses (ICCC-3 or 
Langerhans cell histiocytosis); N=3822; adjusted for sex and age at diagnosis 
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Cancer incidence (2002-2011) in Switzerland, for children aged 0-14 years at 
diagnosis 
Table 5 reports tumours according to ICCC-3 for the last ten years (2002-2011). It 
describes relative frequency, sex ratio, mean age and incidence. Overall more tumours were 
diagnosed in boys than girls. This was true for most types of tumours, except 
neuroblastoma, retinoblastoma, germ cell tumours, and other malignant epithelial 
neoplasms including malignant melanomas. 
The age-standardised incidence (according to the European standard population) of any 
childhood cancer (not including Langerhans cell histiocytosis) was 16.2 per 100,000 person-
years. Incidence was highest among children aged less than 1 year with 24.6 cases per 
100,000 person-years (boys 24.2, girls 25.0). Incidence was lowest in 5-9 year olds with 
12.8 cases per 100,000 person-years (Figure 5 shows crude incidence rates and Figure 6 
shows age- and sex-specific incidence rates for age-groups under 15 years). 
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Table 5 – Number of registered cases in the SCCR for the last 10 years, relative frequency, sex ratio, mean age at diagnosis and 
incidence standardised according to the European standard population, by diagnostic groups according to ICCC-3  
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 2002-2011; all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=1941 
 
 
Diagnosis n 
Relative 
frequency 
Sex ratio 
(male: female) 
Mean age 
at Dx 
Incidence*  
 
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases 588 31.2 1.3 5.0 4.9 
 
a. Lymphoid leukaemias 475 80.8 1.3 4.8 4.0 
 
b. Acute myeloid leukaemias 75 12.8 1.8 7.1 0.6 
 
c. Chronic myeloproliferative diseases 4 0.7 3.0 11.8 0.03 
 
d. Myelodysplastic syndrome and other myeloproliferative diseases 24 4.1 1.2 7.1 0.2 
 
e. Unspecified and other specified leukaemias 10 1.7 0.7 3.1 0.1 
II Lymphomas and reticuloendothelial neoplasms 238 12.6 1.7 10.8 2.0 
 
a. Hodgkin lymphomas 102 42.9 0.9 12.6 0.9 
 
b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 76 31.9 3.0 9.0 0.6 
 
c. Burkitt lymphoma 52 21.8 5.5 7.4 0.4 
 
d. Miscellaneous lymphoreticular neoplasms 7 2.9 0.8 1.3 0.1 
 
e. Unspecified lymphomas 1 0.4 0.0 13.6 0.01 
III CNS and miscellaneous intracranial and intraspinal neoplasms 429 22.7 1.1 7.0 3.6 
 
a. Ependymomas and choroid plexus tumour 34 7.9 1.4 2.4 0.3 
 
b. Astrocytomas 162 37.8 1.3 7.1 1.4 
 
c. Intracranial and intraspinal embryonal tumours 102 23.8 1.3 6.1 0.9 
 
d. Other gliomas 50 11.7 0.6 6.1 0.4 
 
e. Other specified intracranial and intraspinal neoplasms 71 16.6 0.9 11.2 0.6 
 
f. Unspecified intracranial and intraspinal neoplasms 10 2.3 1.0 9.8 0.1 
IV Neuroblastoma and other peripheral nervous cell tumours 125 6.6 0.9 1.1 1.0 
 
a. Neuroblastoma and ganglioneuroblastoma 125 100.0 0.9 1.1 1.0 
V Retinoblastoma 35 1.9 0.7 1.0 0.3 
VI Renal tumours 95 5.0 1.2 3.4 0.8 
 
a. Nephroblastoma and other nonepithelial renal tumours 92 96.8 1.2 3.3 0.8 
 
b. Renal carcinomas 3 3.2 0.5 12.8 0.03 
 
2
4
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Table 5 – continued 
 
Diagnosis n 
Relative 
frequency 
Sex ratio 
(male: female) 
Mean age 
at Dx 
Incidence*  
VII Hepatic tumours 16 0.8 3.0 1.6 0.1 
 
a. Hepatoblastoma 14 87.5 2.5 1.6 0.1 
 
b. Hepatic carcinomas 2 12.5 2.0 7.0 0.0 
VIII Malignant bone tumours 90 4.8 1.0 10.6 0.75 
 
a. Osteosarcomas 40 44.4 0.7 10.9 0.3 
 
c. Ewing tumour and related sarcomas of bone 49 54.4 1.2 10.2 0.4 
 
e. Unspecified malignant bone tumours 1 1.1 0.0 14.7 0.0 
IX Soft tissue and other extraosseous sarcomas 138 7.3 1.3 7.6 1.2 
 
a. Rhabdomyosarcomas 79 57.2 1.3 5.0 0.7 
 
b. Fibrosarcomas, peripheral nerve sheath tumours and other fibrous neoplasms 8 5.8 1.0 8.1 0.1 
 
c. Kaposi sarcoma 1 0.7 0.0 10.0 0.0 
 
d. Other specified soft tissue sarcomas 36 26.1 1.0 11.6 0.30 
 
e. Unspecified soft tissue sarcomas 14 10.1 2.5 2.6 0.1 
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 59 3.1 0.8 8.0 0.5 
 
a. Intracranial and intraspinal germ cell tumours 13 22.0 1.6 8.7 0.1 
 
b. Malignant extracranial and extragonadal germ cell tumours 17 28.8 0.4 1.4 0.1 
 
c. Malignant gonadal germ cell tumours 28 47.5 0.9 10.6 0.2 
 
d. Gonadal carcinomas 1 1.7 0.0 13.9 0.0 
XI Other malignant epithelial neoplasms and malignant melanomas 68 3.6 0.9 11.3 0.6 
 
a. Adrenocortical carcinomas 2 2.9 1.0 6.4 0.0 
 
b. Thyroid carcinomas 14 20.6 0.4 13.1 0.1 
 
c. Nasopharyngeal carcinomas 1 1.5 0.0 12.2 0.0 
 
d. Malignant melanomas 24 35.3 1.4 10.6 0.2 
 
e. Skin carcinomas 9 13.2 1.3 6.2 0.1 
 
f. Other and unspecified carcinomas 18 26.5 0.8 11.5 0.15 
XII Other and unspecified malignant neoplasms 5 0.2 1.5 0.4 0.04 
 
a. Other specified malignant tumours 2 40.0 1.0 6.4 0.02 
 
b. Other unspecified malignant tumours 3 60.0 2.0 0.4 0.03 
 
Total (not including Langerhans cell histiocytosis) 1'886 100 1.2 6.8 15.7 
 
Langerhans cell histiocytosis 55 2.8 1.2 5.0 0.5 
 
Total (including Langerhans cell histiocytosis) 1'941 100 1.2 6.8 16.1 
 
2
5
 
* Incidence: newly diagnosed tumours in a one year time period per 100,000 persons (person-years) 
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Figure 5 – Crude incidence rate (per 100,000 person-years) in Switzerland, by sex 
and year of diagnosis for the last 20 years 
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1992-2011; all diagnoses (ICCC-3 but not 
including Langerhans cell histiocytosis); N=3696 
 
Figure 6 – Age- and sex-specific incidence rates (per 100,000 person-years) in 
Switzerland for the last 10 years 
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 2002-2011; all diagnoses (ICCC-3 but not 
including Langerhans cell histiocytosis); N=1886 
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3.3 Swiss residents aged 15-20 years at diagnosis (N=1815) 
Table 6 reports cases according to ICCC-3 registered in the last ten years (2002-2011), 
diagnosed in adolescent patients (aged 15-20 years at diagnosis). It describes relative 
frequency, sex ratio and mean age at diagnosis. Because data on adolescents is currently 
not population-based within the SCCR, we do not present incidence rates. In adolescents 
the sex ratio is closer to 1 than in those aged 0-14 years.  
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Table 6 – Number of tumours registered in adolescent patients in the SCCR for the last 10 years, relative frequency, sex ratio and 
mean age at diagnosis, by diagnostic groups according to ICCC-3 
Swiss residents; age at diagnosis 15-20 years; period of diagnosis 2002-2011; all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=569 
 
 
Diagnosis n 
Relative 
frequency 
Sex ratio  
(male: female) 
Mean age 
at Dx 
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases 69* 12.1 1.5 16.5 
 
a. Lymphoid leukaemias 38 55.1 1.9 16.1 
 
b. Acute myeloid leukaemias 16 23.2 1.3 15.9 
 
c. Chronic myeloproliferative diseases 6 8.7 1.0 18.8 
 
d. Myelodysplastic syndrome and other myeloproliferative diseases 3 4.3 0.5 17.7 
 
e. Unspecified and other specified leukaemias 1 1.4 0.0 18.9 
II Lymphomas and reticuloendothelial neoplasms 147* 25.9 0.7 17.0 
 
a. Hodgkin lymphomas 91 61.9 0.6 17.0 
 
b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 34 23.1 0.9 17.0 
 
c. Burkitt lymphoma 7 4.8 1.3 18.4 
 
d. Miscellaneous lymphoreticular neoplasms 1 0.7 0.0 16.6 
III CNS and miscellaneous intracranial and intraspinal neoplasms 94* 16.5 1.0 16.7 
 
a. Ependymomas and choroid plexus tumour 10 10.6 0.4 18.5 
 
b. Astrocytomas 32 34.0 0.8 16.7 
 
c. Intracranial and intraspinal embryonal tumours 17 18.1 1.4 16.0 
 
d. Other gliomas 7 7.4 1.3 17.1 
 
e. Other specified intracranial and intraspinal neoplasms 25 26.6 1.3 16.5 
 
f. Unspecified intracranial and intraspinal neoplasms 2 2.1 1.0 18.5 
IV Neuroblastoma and other peripheral nervous cell tumours 0 0.0 0.0 0.0 
V Retinoblastoma 0 0.0 0.0 0.0 
VI Renal tumours 9 1.6 0.8 17.1 
 
a. Nephroblastoma and other nonepithelial renal tumours 4 44.4 1.0 16.4 
  b. Renal carcinomas 5 55.6 0.7 17.5 
 
  
 
2
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Table 6 – continued 
 
 
Diagnosis n 
Relative 
frequency 
Sex ratio  
(male: female) 
Mean age 
at Dx 
VII Hepatic tumours 5 0.9 1.5 16.1 
 
a. Hepatoblastoma 5 100.0 1.5 16.1 
VIII Malignant bone tumours 47* 8.3 1.8 16.3 
 
a. Osteosarcomas 34 72.3 1.8 16.3 
 
c. Ewing tumour and related sarcomas of bone 10 29.4 1.5 16.6 
 
d. Other specified malignant bone tumours 2 20.0 1.0 16.7 
IX Soft tissue and other extraosseous sarcomas 37* 6.5 0.7 16.8 
 
a. Rhabdomyosarcomas 16 43.2 0.8 16.0 
 
d. Other specified soft tissue sarcomas 17 45.9 0.5 18.0 
 
e. Unspecified soft tissue sarcomas 3 8.1 0.5 16.8 
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 46* 8.1 10.5 19.1 
 
a. Intracranial and intraspinal germ cell tumours 2 4.3 0.0 18.0 
 
c. Malignant gonadal germ cell tumours 40 87.0 12.3 19.1 
 
d. Gonadal carcinomas 1 2.2 0.0 15.4 
XI Other malignant epithelial neoplasms and malignant melanomas 112* 19.7 0.8 18.6 
 
a. Adrenocortical carcinomas 1 0.9 0.0 17.0 
 
b. Thyroid carcinomas 21 18.8 0.3 18.4 
 
c. Nasopharyngeal carcinomas 3 2.7 0.0 17.9 
 
d. Malignant melanomas 51 45.5 0.7 18.7 
 
e. Skin carcinoma 8 7.1 0.3 18.6 
 
f. Other and unspecified carcinomas 18 16.1 3.5 18.2 
XII Other and unspecified malignant neoplasms 2 0.4 1.0 18.0 
 
a. Other specified malignant tumours 2 100.0 1.0 18.0 
 
Total (not including Langerhans cell histiocytosis) 568 100.0 1.1 17.6 
 
Langerhans cell histiocytosis 1 0.2 0.0 17.0 
 
Total (including Langerhans cell histiocytosis) 569 100.0 1.1 17.6 
*This total includes tumours where only main group is available due to lack of detailed medical information  
 
2
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4. Research projects on childhood cancer 
Table 7 summarises recent or current research projects of the childhood cancer registry. All 
projects are described in more detail in the remainder of Chapter 4, and additional 
information is available from the references and from the investigators. We thank the 
supporters listed in Table 7 for their generous contributions towards the research projects. 
 
Table 7 – Research projects at the SCCR 
No Project name Funding 
Primary 
investigator 
Study 
Type 
Study 
period 
1 Swiss Childhood Cancer Survivor Study 
(SCCSS) 
Swiss Cancer League 
Cancer League Aargau 
Cancer League Zürich 
Swiss Bridge Foundation 
Von der Weid 
NX 
Kuehni CE 
Cohort 
study  
01.2006-
12.2013 
2 An international case-control study on 
brain tumours in children and adolescents 
(CEFALO) 
Swiss National Science 
Foundation 
Mobilfunkstiftung 
Röösli M Case-
control 
study 
10.2005-
12.2008 
3 Childhood cancer and nuclear power 
plants in Switzerland (CANUPIS) 
Federal Office of Public 
Health 
Swiss Cancer League 
Kuehni CE Cohort 
study 
09.2008-
12.2010 
4 Follow-up care after childhood and young 
adult cancer (CCFU) 
Swiss National Science 
Foundation 
Michel G Cohort 
study 
08.2009-
07.2014 
5 Risk of cancer and long-term mortality in 
children treated with Growth Hormone: 
Swiss participation in the EU FP7 project 
“SAGhE” 
EU FP7 
Swiss Cancer League 
Mullis PE 
Kuehni CE 
Cohort 
study 
01.2010-
12.2013 
6 PanCare childhood and adolescent cancer 
survivor care and follow-up studies 
(PanCareSurFup) 
EU FP7 
Cancer Research 
Switzerland 
Kuehni CE 
Michel G 
Cohort 
study 
02.2011-
01.2016 
7 Childhood cancer and vicinity of residence 
to petrol stations and major roads: a 
census-based nationwide cohort study 
(PETROL) 
Federal Office of Public 
Health 
Kuehni CE 
Feller M 
Cohort 
study 
06.2010-
12.2012 
8 Developing a radon exposure model to 
predict domestic radon exposure for Swiss 
children 
Swiss National Science 
Foundation 
Röösli M Cohort 
study 
01.2011-
12.2013 
9 Effectiveness of transition from paediatric 
to adult care after childhood cancer 
Swiss Cancer League Michel G Cohort 
study 
04.2011-
03.2014 
10 Mortality and second primary neoplasms 
after cancer in childhood and adolescence 
Swiss National Science 
Foundation 
Swiss Bridge Foundation 
Kuehni CE 
Michel G 
Egger M 
Cohort 
study 
11.2012-
10.2015 
11 Childhood cancer and geographically 
defined exposures in Switzerland: a 
census-based nationwide cohort study 
Federal Office of Public 
Health 
Kuehni CE 
Spycher B 
Cohort 
study 
01.2013-
11.2014 
12 The role of population mixing and 
exposure to infections in the aetiology of 
childhood leukaemia: a national 
cohort study 
Cancer Research 
Switzerland 
Spycher B Cohort 
study 
01.2013-
12.2014 
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4.1 Swiss Childhood Cancer Survivor Study (SCCSS) 
Background: Thanks to therapeutic improvements in the past decades, survival rates for 
childhood cancer now exceed 80%, leading to a growing population of long-term survivors. 
However, cancer and cancer treatments have been associated with adverse late effects and 
the health and quality of life of survivors are of increasing concern. In Switzerland and 
other countries, comprehensive data on the burden of late effects of childhood cancer and 
its risk factors, as well as data on the use of follow-up care in long-term survivors is scarce. 
Objectives: This project investigates long-term outcomes of childhood cancer survivors, 
diagnosed with cancer before the age of 21 years and who survived for more than 5 years. 
It studies the incidence and spectrum of various somatic and psycho-social outcomes 
including late mortality, second primary malignancies, somatic health and medication, 
mental health, educational achievements, health related quality of life, and their association 
with a number of risk factors assessed prospectively at time of diagnosis (tumour, treatment 
modalities, demographic characteristics). Current practices of health-care provision and 
health behaviour in long-term survivors are also investigated. 
Methods: This is a prospective cohort study based on the population of children and 
adolescents registered in the SCCR. All individuals who have been diagnosed with cancer 
before 31 December 2005 when aged <21 years, who are still alive, and who were Swiss 
residents at time of diagnosis are eligible for the study. A detailed questionnaire is being 
sent to all participants. Questionnaire data are validated with information provided by 
general practitioners and hospital records. For comparison, the same questionnaire is sent 
to all siblings of childhood cancer survivors who answered the questionnaire. 
Current status of the project: By 31 December 2012, we have contacted 2930 survivors 
aged 0-16 years at time of diagnosis. Of these, 2160 answered our questionnaire (74%). 
These include 1284 adult survivors aged >20 years (76% of those contacted), as well as 
447 adolescent survivors aged 15-20 years (67% of those contacted) and 429 parents of 
children agend <15 years (73% of those contacted). In autumn 2012, we started to contact 
former patients who were diagnosed at age 16-20 years. Of the 1530 siblings that could be 
traced and contacted, a total of 819 (54%) answered the questionnaire. Among them 
were 578 adults (59%), 135 adolescents (44%) and 106 parents of children (42%).  
Applicants: Kuehni CE, Egger M, Zwahlen M, Rebholz CE, Rueegg CS. Institute of Social 
and Preventive Medicine, University of Bern; von der Weid NX. Paediatric Oncology, 
University Children’s Hospital Basel (UKBB); Niggli F, Bergstraesser E. University Children’s 
Hospital, Zurich; Angst R. Children’s Hospital Aarau; Probst-Hensch N. Swiss Tropical & 
Public Health Institute, University of Basel. 
Project team: Kuehni CE, Wengenroth L, Rueegg CS, Essig S, Koch J, Liechti F, 
Brantschen E, Michel G. Institute of Social and Preventive Medicine, University of Bern; 
von der Weid NX. Paediatric Oncology, University Children’s Hospital Basel (UKBB) 
Funding: Swiss Cancer League (Grant No KLS 01605-10-2004 and KLS 2215-02-2008), 
Stiftung zur Krebsbekämpfung, Swiss Bridge Foundation, Bernese Cancer League, Cancer 
League Zurich and Cancer League Aargau. 
  
 
 
32 
Contact: Claudia Kuehni (kuehni@ispm.unibe.ch);  
Laura Wengenroth (lwengenroth@ispm.unibe.ch) 
 
Publications (published):  
Michel G, Rebholz CE, von der Weid NX, Bergstraesser E, Kuehni CE. Psychological distress 
in adult survivors of childhood cancer: the Swiss Childhood Cancer Survivor Study. Journal 
of Clinical Oncology 2010; 28:1740-1747. 
Marquis A, Kuehni CE, Strippoli MPF, Kuehne T, Brazzola P. Sperm analysis of patients after 
successful treatment of childhood acute lymphoblastic leukemia with chemotherapy. 
Pediatric Blood & Cancer 2010; 55: 208–210. 
Rebholz CE, von der Weid NX, Michel G, Niggli F, Kuehni CE. Follow-up care amongst long-
term childhood cancer survivors: a report from the Swiss Childhood Cancer Survivor Study. 
European Journal of Cancer 2011; 47: 221-229. 
Michel G, Kuehni CE, Rebholz CE, Zimmermann K, Eiser C, Rueegg CS, von der Weid NX. 
Can health beliefs help explaining attendance to follow-up care? The Swiss Childhood 
Cancer Survivor Study. Psycho-Oncology 2011; 20: 1034-1043. 
Marquis A, Strippoli MPF, Spycher BD, Rebholz CE, von der Weid NX, Kuehni CE. 
Paracetamol, nonsteroidal anti-inflammatory drugs, and risk of asthma in adult survivors of 
childhood cancer. Journal of Allergy and Clinical Immunology 2011; 127: 270-272. 
Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MP, Niggli FK, Egger M, von der 
Weid NX. Cohort Profile: The Swiss Childhood Cancer Survivor Study. International Journal 
of Epidemiology 2012; 41: 1553-1564. 
Rueegg CS, von der Weid NX, Rebholz CE, Michel G, Zwahlen M, Grotzer M, Kuehni CE. 
Daily physical activities and sport in adult survivors of childhood cancer and healthy controls: 
a population-based questionnaire survey. PLoS ONE 2012; 7: e34930. 
Rebholz CE, Rueegg CS, Michel G, Ammann RA, von der Weid NX, Kuehni CE, Spycher BD. 
Clustering of health behaviours in adult survivors of childhood cancer and the general 
population. British Journal of Cancer 2012; 107: 234-242. 
Kuehni CE, Strippoli MPF, Rueegg CS, Rebholz CE, Bergstraesser E, Grotzer M, von der 
Weid NX Michel G. Educational achievement in Swiss childhood cancer survivors compared 
with the general population. Cancer 2012; 118: 1439-1449. 
Rebholz CE, Kuehni CE, Strippoli MP, Rueegg CS, Michel G, Hengartner H, Bergstraesser E, 
von der Weid NX. Alcohol consumption and binge drinking in young adult childhood cancer 
survivors. Pediatric Blood & Cancer 2012; 58: 256-264. 
Essig S, von der Weid NX, Strippoli MP, Rebholz CE, Michel G, Rueegg CS, Niggli FK, Kuehni 
CE. Health-related quality of life in long-term survivors of relapsed childhood acute 
lymphoblastic leukemia. PLoS ONE. 2012; 7: e38015. 
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Rueegg CS, Michel G, Wengenroth L, von der Weid NX, Bergstraesser E, Kuehni CE. Physical 
performance limitations in adolescent and adult survivors of childhood cancer and their 
siblings. PLoS ONE 2012; 7: e47944. 
Gianinazzi ME, Rueegg CS, Wengenroth L, Bergstraesser E, Rischewski J, Ammann RA, 
Kuehni CE, Michel G. Adolescent survivors of childhood cancer: are they vulnerable for 
psychological distress? Psycho-Oncology 2013; doi:10.1002/pon.3249. 
Publications (submitted):  
Lupatsch J, Wengenroth L, Rueegg CS, Teuffel MO, Gumy-Pause F, Kuehni CE & Michel G. 
Follow-up care of adolescent cancer survivors: the role of health-beliefs.  
Gianinazzi ME, Rueegg CS, Wengenroth L, Niggli FK, Kuehni CE, Michel G. Psychological 
care in adult survivors of childhood cancer and siblings: the Swiss Childhood Cancer Survivor 
Study.  
Rueegg CS*, Gianinazzi ME*, Rischewski J, Beck Popovic M, von der Weid NX, Michel G, 
Kuehni CE. Quality of life in childhood cancer survivors: the role of chronic health problems. 
*shared first authorship with equal contributions. 
Heg Z, Gianinazzi ME, Rueegg CS, Bergstraesser E, von der Weid NX, Tinner EM, Kuehni CE, 
Michel G. Longitudinal changes in psychological distress in childhood cancer survivors.  
Rueegg CS, Gianinazzi ME, Michel G, Zwahlen M, von der Weid NX, Kuehni CE. 
Characteristics of responders and non-response bias in a nationwide follow-up study of 
childhood cancer survivors. 
Rueegg CS, Gianinazzi ME, Michel G, von der Weid NX, Bergstraesser E, Kuehni CE. Do 
childhood cancer survivors with physical performance limitations reach healthy activity levels?  
 
4.2 An international case-control study on brain tumours in children 
and adolescents (CEFALO) 
Background: It was hypothesized that children might be more vulnerable to radio 
frequency electromagnetic field exposures from mobile telephones than adults. Decision-
makers issued conflicting recommendations because not enough data was available, which 
led to anxiety and insecurity in the population. In their 2006 research agenda, WHO put a 
high priority on a case-control study on radio frequency electromagnetic fields and 
childhood brain tumours in order to address these concerns. 
Objectives: The study was designed to determine if use of mobile telephones increases risk 
of brain tumours in children or adolescents. In addition, other potential risk factors for 
childhood brain tumours were investigated. 
Study design: The questions were investigated through an international case-control study 
in Denmark, Norway, Sweden and Switzerland. Cases were identified by combining registry 
data and information from the wards where the cases were treated (e.g. Swiss Paediatric 
Oncology Group). All incident cases of brain tumour at age 7-19 years between May 2004 
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and April 2008 were invited to participate. In total, the study included 550 cases of brain 
tumours in all participating countries; 100 originated in Switzerland. For each case, two 
control persons were randomly selected from the general population, matched on age, sex 
and geographic region. 
Exposure assessment: Information on the extent of exposure to radio frequency fields 
from mobile phones, and on other known and suspected risk factors for childhood brain 
tumours was obtained by means of computer assisted personal interviews. Objective 
information on the frequency and duration of mobile phone use was obtained from mobile 
phone operators and from the information stored in the telephone in current use. 
Data analyses: The data was analysed using statistical methods for case-control studies, 
primarily via conditional logistic regression models adjusted for potential confounders.  
Current status of the project: Data collection has been completed for cases and controls 
and several papers have been published. Additional analyses are still on-going. 
Applicants: Röösli M. Swiss Tropical and Public Health Institute Basel; Kuehni CE. Institute 
of Social and Preventive Medicine, University of Bern; Grotzer M. University Children’s 
Hospital, Zurich; Feychting M. Karolinska Institutet, Stockholm; Tynes T. Cancer Registry of 
Norway, Oslo; von der Weid NX. Paediatric Oncology, University Children’s Hospital Basel 
(UKBB); Schuetz J. International Agency for Research on Cancer (IARC), Section of 
Environment and Radiation, Lyon, France. 
Project team: Aydin D, Röösli M. Swiss Tropical and Public Health Institute Basel; Kuehni 
CE. Institute of Social and Preventive Medicine, University of Bern. 
Funding: Swiss Federal Office of Public Health (Grant No 05.001626), Swiss Research 
Foundation on Mobile Communication (Grant No A2006.18), and Swiss National Science 
Foundation (Grant No PDFMP3_122873). 
Contact: Martin Röösli (martin.roosli@unibas.ch) 
Publications (published):  
Aydin D, Feychting M, Schüz J, Tynes T, Andresen TV, Schmidt LS, Poulsen AH, Johansen C, 
Prochazka M, Lannering B, Klaeboe L, Eggen T, Jenni D, Grotzer M, von der Weid NX, 
Kuehni CE, Röösli M. Mobile phone use and brain tumors in children and adolescents: a 
multicenter case-control study. Journal of the National Cancer Institute 2011; 103: 1264-
1276. 
Aydin D, Feychting M, Schüz J, Andersen TV, Poulsen AH, Prochazka M, Klæboe L, Kuehni 
CE, Tynes T, Röösli M. Impact of random and systematic recall errors and of selection bias in 
case-control studies on mobile phone use and brain tumours in adolescents (CEFALO study). 
Bioelectromagnetics 2011; 32: 396-407. 
Aydin D, Feychting M, Schüz J, Andersen TV, Poulsen AH, Prochazka M, Klæboe L, Kuehni 
CE, Tynes T, Röösli M. Predictors and overestimation of recalled mobile phone use among 
children and adolescents. Progress in Biophysics and Molecular Biology 2011; 107: 356-361.  
Aydin D, Feychting M, Schüz J, Röösli M. Childhood brain tumours and use of mobile 
phones: Comparison of a case-control study with incidence data. Environmental Health 
2012; 11: 35. 
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Christensen JS, Mortensen LH, Röösli M, Feychting M, Tynes T, Andersen TV, Schmidt LS, 
Poulsen AH, Aydin D, Kuehni CE, Prochazka M, Lannering B, Klaeboe L, Eggen T, Schüz J. 
Brain tumors in children and adolescents and exposure to animals and farm life: a 
multicenter case-control study (CEFALO). Cancer Causes and Control 2012; 23: 1463-1473. 
Publications (submitted):  
Andersen TV, Schmidt LS, Poulsen AH, Feychting M, Röösli M, Tynes T, Aydin D, Prochazka 
M, Lannering B, Klæboe L, Eggen T, Kuehni CE, Schmiegelow K, Schüz J. Patterns of 
exposure to infectious diseases and social contact in early life and risk of brain tumours in 
children and adolescents: an International Case-Control Study (CEFALO). 
 
4.3 Childhood cancer and nuclear power plants in Switzerland 
(CANUPIS) 
Background: Since a cluster of leukaemia cases around Sellafield was reported in 1984, 
many studies have investigated associations between childhood cancer and residence near 
nuclear power plants (NPPs). The results of these studies were heterogeneous and many 
found weak positive associations.  
Objectives: To investigate possible associations between residence near a NPP and the risk 
of childhood cancer, and childhood leukaemia in particular. 
Methods: This was a census-based cohort study with national coverage. To estimate 
person-years at risk, the study used the Swiss National Cohort (SNC), a long-term, census-
based, multipurpose cohort and research platform that includes all Swiss inhabitants. Cases 
were identified from the Swiss Childhood Cancer Registry (SCCR) and all cases born 
between January 1985 and December 2007 and aged 0-15 years at diagnosis were 
included. For these individuals we reconstructed address histories back to birth by 
contacting municipal population registers. We geocoded all addresses and calculated 
distances to nearest NPPs. Using Poisson regression we calculated incidence rate ratios 
(IRRs) comparing the risk of cancer in children living 0-5 km, 5-10 km, 10-15 km to those 
living >15 km from a NPP at birth (primary analysis) and at diagnosis (secondary analysis). 
The following potential confounders were included: background ionizing radiation (cosmic, 
terrestrial artificial and total radiation); electromagnetic radiation from radio and TV 
transmitters, railway tracks, and high voltage power lines; distance to major roads; 
agricultural pesticides (based on land-use statistics); and, community level socio-economic 
and demographic indicators (degree of urbanisation, Sotomo-Index and average number of 
children per household). We assessed robustness of results in numerous sensitivity analyses.  
Current status of project: We included 2925 children diagnosed with cancer over 21 
million person-years of follow-up; 953 (32.6%) were diagnosed with leukaemia. Eight and 
12 children who were diagnosed with leukaemia at ages 0–4 and 0–15 years, and 18 and 
31 children who were diagnosed with any type of cancer lived within 5km of a NPP. 
Compared with children born >15km away, the IRRs (95% CI) for leukaemia in 0–4 and 0–
15 year olds were 1.20 (0.60–2.41) and 1.05 (0.60–1.86), respectively. For any cancer, 
corresponding IRRs were 0.97 (0.61–1.54) and 0.89 (0.63–1.27). There was no evidence of 
a dose–response relationship with distance (P>0.30). Results were similar for residence at 
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diagnosis and at birth, and when adjusted for potential confounders. Results from sensitivity 
analyses were consistent with main results. 
Conclusions and significance: This study found little evidence for an association between 
risk of childhood cancer and residence near NPPs. This study contributes importantly to 
the current evidence base in this field of research. Because the study was nationwide, and 
thus virtually free of selection bias, used exact geocodes of place of residence at birth and 
at diagnosis, and adjusted for a wide range of confounders, it overcame some significant 
methodological limitations of previous studies.  
Applicants: Kuehni CE. Institute of Social and Preventive Medicine, University of Bern; 
Röösli M. Swiss Tropical and Public Health Institute, University of Basel; von der Weid NX. 
Paediatric Oncology, University Children’s Hospital Basel (UKBB); Hengartner H. Children’s 
Hospital, St. Gallen; Niggli F. University Children’s Hospital, Zurich; Egger M. Institute of 
Social and Preventive Medicine, University of Bern. 
Project team: Feller M, Kuehni CE, Spycher BD, Zwahlen M, Gueler A, Institute of Social 
and Preventive Medicine, University of Bern; Röösli M. Swiss Tropical and Public Health 
Institute, University of Basel. 
Funding: Federal Office of Public Health (Grant No 08.001616) and Swiss Cancer League 
(Grant No KLS 02224-03-2008). 
Contact: Claudia Kuehni (kuehni@ispm.unibe.ch) 
Publications:  
Spycher BD*, Feller M*, Zwahlen M, Röösli M, von der Weid N, Hengartner H, Egger M, 
Kuehni CE. Childhood cancer and nuclear power plants in Switzerland: a census-based 
cohort study. International Journal of Epidemiology 2011; 40: 1247-1260. *shared first 
authorship with equal contributions 
Spycher BD, Kuehni CE, Zwahlen M, Egger M. Authors' response to: Childhood cancer and 
nuclear power plants in Switzerland: a census-based cohort study. International Journal of 
Epidemiology 2012; 41: 321-322. 
Kuehni CE, Feller M, Egger M. Response to: Sufficient statistical power for CANUPIS? 
Schweizer Krebsbulletin 2009; 4.09: 301. 
 
4.4 Follow-up care after childhood and young adult cancer (CCFU) 
Background: Treatment for cancer in children and young adults has greatly improved and 
most patients are being cured today. However, more than 50% of survivors of childhood 
cancer suffer from late effects. To detect and treat late effects as early as possible, survivors 
must continue to have follow-up care long after their cancer has been cured. Various 
models of follow-up care have been described, but so far none has been implemented in 
Switzerland. While follow-up care needs to be constantly updated to meet the current 
status of research, survivor participation is only ensured if follow-up is convenient. 
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Objectives: 1) To compare the advantages and disadvantages of follow-up care models 
currently used in Europe; 2) To determine the current availability and use of follow-up care 
in survivors of childhood and young adult cancers in Switzerland; and, 3) To determine the 
advantages and disadvantages of follow-up care models as perceived by survivors, 
oncologists and family practitioners, and to compare their views and opinions. 
Methods: For part 1), we invited 198 clinics and follow-up programmes in Europe to 
complete a questionnaire survey describing the follow-up care available at their institution. 
For part 2), we analysed the current use of follow-up care together with the 
psychological well-being in childhood cancer survivors, using data from the Swiss 
Childhood Cancer Survivor Study (SCCSS). In part 3), a questionnaire survey assessed 
opinions and perspectives on both, currently used and desired optimal follow-up care. 
The sample includes childhood, adolescent and young adult cancer survivors diagnosed with 
cancer between 1990 and 2005 and aged <25 years, who survived for >5 years and who 
are currently aged 11+ years. In addition, paediatric and adult oncologists/haematologists 
and family practitioners have completed a questionnaire. 
Rationale and significance: This project provides an overview of follow-up care in Europe 
and will describe survivor, oncologist and family practitioner preferences for follow-up care 
models in Switzerland. We will determine the differences between the three groups in order 
to improve follow-up care and adapt it to differing preferences. The project will provide the 
basis for the development of a standardised model of follow-up care for childhood cancer 
survivors in Switzerland. 
Current status of project: A first paper on follow-up care after childhood cancer in Europe 
has been published. The questionnaire survey on follow-up care after childhood cancer has 
been completed for survivors of childhood cancer, paediatric and medical oncologists, and 
general practitioners, but is still on-going for parents of childhood cancer survivors and 
survivors of adolescent and young adult cancer. Papers on the use of follow-up care by 
survivors have been published. 
Applicant: Michel G. Institute of Social and Preventive Medicine, University of Bern.  
Project team: Michel G, Kuehni CE, Lupatsch J, Heg-Bachar Z. Institute of Social and 
Preventive Medicine, University of Bern; von der Weid NX. Paediatric Oncology, University 
Children’s Hospital Basel (UKBB); Niggli F. University Children’s Hospital, Zurich. 
Funding: Swiss National Science Foundation (Division Individual Funding “Ambizione” 
Grant No PZ00P3_121682/1 and PZ00P3_141722/1). 
Collaborations: Eiser C, Greenfield D. Child and Family Research Group, University of 
Sheffield; Hjorth L, Skinner R, Haupt R, PanCare (European network of professionals, 
survivors and their families established to ensure that every European survivor of childhood 
and adolescent cancer receives optimal long-term care). 
Contact: Gisela Michel (michel@ispm.unibe.ch) 
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Publications (published):  
Michel G, Rebholz CE, von der Weid NX, Bergstraesser E, Kuehni CE. Psychological distress in 
adult survivors of childhood cancer: the Swiss Childhood Cancer Survivor Study. Journal of 
Clinical Oncology 2010; 28: 1740-1747. 
Michel G, Kuehni CE, Rebholz CE, Zimmermann K, Eiser C, Rueegg CS, von der Weid NX. Can 
health beliefs help in explaining attendance to follow-up care? The Swiss Childhood Cancer 
Survivor Study. Psycho-Oncology 2011; 20: 1034-1043. 
Michel G, Greenfield D, Absolom K, Eiser C. Follow-up care after childhood and young adult 
cancer: Satisfaction and associations with coping style. Psycho-Oncology 2011; 20: 813-822. 
Rebholz CE, von der Weid NX, Michel G. Niggli F, Kuehni CE. Follow-up care amongst long-
term childhood cancer survivors: a report from the Swiss Childhood Cancer Survivor Study. 
European Journal of Cancer 2011; 47: 221-229. 
Michel G. Nachsorge nach Krebs im Kindesalter – Ein neues Feld für die Pflege? 
Onkologiepflege 2011. 3, 20-23. 
Michel G. Nachsorge nach Krebs im Kindesalter. Schweizer Krebsbulletin 2012. 3, 212-213. 
Essig S, von der Weid NX, Skinner R, Kuehni CE, Michel G. Follow-up programs for childhood 
cancer survivors in Europe: a questionnaire survey. PLoS ONE 2012; 7: e53201. 
Publications (submitted):  
Singer S, Gianinazzi ME, Hohn A, Kuehni CE, Michel G. GP-led follow-up after childhood 
cancer – a systematic review. 
Heg Z, Gianinazzi ME, Rueegg CS, Bergstraesser E, von der Weid NX, Tinner EM, Kuehni CE, 
Michel G. Longitudinal changes in psychological distress in childhood cancer survivors.  
Lupatsch J, Wengenroth L, Rueegg CS, Teuffel MO, Gumy-Pause F, Kuehni CE, Michel G. 
Follow-up care of adolescent cancer survivors: the role of health-beliefs. 
 
4.5 Risk of cancer and long-term mortality in children treated with 
growth hormone: Swiss participation in the EU FP7 project 
“SAGhE” 
Background: Recombinant human growth hormone (GH) was initially used to treat cases of 
primary severe growth hormone deficiency (GHD) but its uses have multiplied. GHD is the 
most common endocrine late effect of childhood cancer treatment, especially after brain 
tumours and cranial irradiation. Efficacy of GH treatment in children with severe GHD is 
undisputed and short term safety during treatment is satisfactory. Data on efficacy for other 
indications, association with quality of life and long-term safety are scarce. Several 
experimental studies have raised concerns about cancer risk and long-term mortality. 
Therefore, an international consortium with investigators from nine countries decided to 
study “Safety and Appropriateness of Growth hormone treatments in Europe” (SAGhE).  
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Objectives: To establish a cohort of young adults treated with GH in childhood due to 
different diagnoses; describe the indications and frequency of GH use for children in 
Switzerland since 1985; assess long-term efficacy and quality of life in adulthood after GH-
treatment in childhood; and to investigate long-term safety of GH-treatment in childhood, 
in particular risk of cancer and mortality. 
Methods: To identify all eligible patients, we collect information from the following sources: 
a) patients treated in all paediatric endocrinology centres in Switzerland; b) registries (the 
SCCR and the Swiss Paediatric Renal Registry) and industrial databases. Relevant data are 
extracted from hospital records. Quality of life is assessed via questionnaire surveys. Incident 
cancers are assessed via linkage with the SCCR and cantonal cancer registries and via 
questionnaire survey. Date and place of death is obtained via municipal population registers, 
causes of death are obtained from the Swiss Federal Statistical Office. The risk of cancer and 
mortality in the cohort is compared to the risk in the general population by calculating 
standardized incidence ratios and standardized mortality ratios. For diagnoses with 
increased baseline risks (childhood cancer survivors, chronic renal failure), we compare risk 
in GH-treated patients to that of untreated patients with similar diagnoses. 
Rationale and significance: The project will describe the use of GH in Switzerland and 
analyse long-term safety in the context of a high-quality international collaborative study. 
Results will be presented to the public, guidelines committees and health authorities and 
will likely influence future recommendations for treatment with GH in children, particularly 
in children suffering from cancer. Furthermore, prospective data collection will continue and 
serve as a resource for future research. 
Current status of project: We identified 1692 patients treated with GH during childhood. 
Patients older than 18 years were included in the SAGhE study (N=754). We completed data 
collection for this age group. We assessed health related quality of life (HRQoL) for patients 
over 18 years via postal questionnaire. A total of 610 patients were eligible and 333 
patients answered the questionnaire (response rate 55%). We linked the growth registry 
with the SCCR to identify incident cancer during childhood. A linkage with cantonal cancer 
registries to detect incident cancers in adulthood is still in process. Only 2% of the patients 
have died (N=14).  
Applicants: Mullis PE. Department for Paediatric Endocrinology, Diabetology and 
Metabolism, University Children’s Hospital, Bern; Kuehni CE, Bohlius J. Institute of Social 
and Preventive Medicine, University of Bern; Grotzer M. University Children’s Hospital, 
Zurich; Clough-Gorr K. NICER, Institute of Social and Preventive Medicine, University of 
Zurich; Stettler C. Division of Endocrinology, Diabetes, and Clinical Nutrition, University 
Hospital of Bern. 
Project team: Sommer G, Kuonen R, Kuehni CE. Institute of Social and Preventive Medicine, 
University of Bern; Mullis PE. Department for Paediatric Endocrinology, Diabetology and 
Metabolism, University Children’s Hospital, Inselspital Bern. 
Funding: European Union FP7: HEALTH.2007-3.1-5: Better use of medicines, Swiss Cancer 
League (Grant No KLS 02586-02-2010 and KLS 2948-02-2012). 
Contact: Grit Sommer (gsommer@ispm.unibe.ch); Claudia Kuehni (kuehni@ispm.unibe.ch) 
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Publications: Expected for 2013-2014. 
Published abstracts:  
Sommer G, Kuehni CE, Karabulut F, Stettler C, Mullis PE, for the Swiss Association for 
Paediatric Endocrinology and Diabetology. The Swiss Growth Registry: aims, methods and 
first results. Swiss Medical Weekly 2012; 142: 8S. 
Karabulut F, Sommer G, Mullis PE, Kuehni CE. Quality of life of young adults treated with 
recombinant human Growth Hormone during childhood. Swiss Medical Weekly 2012; 142: 
19S. 
 
4.6 PanCare childhood and adolescent cancer survivor care and 
follow-up studies (PanCareSurFup) 
Background: Long-term survival after childhood cancer exceeds 80%, but two third of 
survivors develop chronic conditions. Also late mortality is increased as a consequence of the 
cancer and its treatment. More than ten years after diagnosis, deaths from second primary 
cancers and circulatory causes predominate. There is thus a compelling need to identify 
avoidable risk factors for these late effects. Due to small numbers of survivors in single 
countries, a combination of datasets is essential to tackle these questions.  
Objectives: 1) To establish a cohort of 5-year survivors of childhood cancer; 2) to analyse 
incidence and risk factors for second primary cancers, late cardiovascular diseases and late 
mortality; 3) to perform nested case-control studies on second primary sarcomas, second 
primary carcinomas and late cardiovascular diseases; and 4) to develop guidelines for the 
clinical follow-up of survivors.  
Methods: 1) The cohorts of survivors of childhood cancer of the 11 participating European 
countries will be combined into a pan-European “PanCareSurFup cohort”. 2) For all cohort 
members, we are collecting vital status and date of death via municipal population registers 
and Swiss mortality statistics. Cardiovascular late effects and second primary cancers are 
identified via: a) questionnaires to all survivors; b) mortality records (for deceased); and, c) 
linkage with cantonal cancer registries (for second primary cancers). Patient-reported 
diseases from the questionnaire are validated with medical records. 3) Case-control studies: 
From the cohort, Switzerland will sample 50 cases with severe cardiovascular disease, 55 
cases with second primary sarcoma or carcinoma and 105 controls. For these we will extract 
details of radio- and chemotherapy from medical records, and assess current health 
problems and environmental, social and lifestyle risk factors by interview. 4) In close 
collaboration with experts from across Europe, we will write systematic reviews to develop 
evidence-based, standardised guidelines.  
Rationale and significance: This research project provides a unique opportunity to study 
the most severe and life threatening late effects of childhood and adolescent cancer in an 
international setting that maximises statistical power and generalizability of results. The 
identification of avoidable causes for cardiovascular late effects and second primary cancers 
will allow treatment to be adapted for new patients. The goal is maximal cure rates with 
minimal long-term side effects.  
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Current status of project: We included 4760 5-year survivors from Switzerland into the 
“PanCareSurFup” cohort. For all cohort members, we updated vital status, and ascertained 
date and cause of death. The questionnaire survey will be completed in 2013. By December 
2012, we identified 316 patients reporting cardiovascular problems in the questionnaire. 
Additional 59 survivors were identified via the SCCR and 26 by linking with the Swiss 
mortality statistics. To validate outcomes, we are contacting general practitioners and 
performing phone interviews with survivors. We identified 95 survivors who developed a 
second primary neoplasm. Linkage with cantonal cancer registries to detect additional 
second primary cancers is in process. 
Applicants: Kuehni C, Michel G, Institute of Social and Preventive Medicine (ISPM) 
University of Bern, von der Weid N, Paediatric Oncology, University Children’s Hospital Basel 
(UKBB), Bergstraesser E, Centre of clinical research, University of Zurich, Kretschmar O, 
Paediatric cardiology, University of Zurich. 
Project team: Kuehni C, Michel G, Hau E, Schindler M. ISPM, University of Bern, von der 
Weid NX, Paediatric Oncology, University Children’s Hospital Basel (UKBB), Bergsträsser E, 
Centre of clinical research, University of Zurich, Kretschmar O, Pediatric cardiology, 
University of Zurich 
Funding: European Union FP7: HEALTH.2010.2.4.1-7: Predicting long-term side effects to 
cancer therapy. Cancer Research Switzerland (Grant No KFS 02783-02-2011). 
Contact: Eva Hau (ehau@ispm.unibe.ch); Claudia Kuehni (kuehni@ispm.unibe.ch) 
Publication (in preparation):  
Hau EM, Berner L, Essig S, Michel G, Bergstraesser E, Kuehni CE. Validation of self-reported 
cardiovascular problems by contacting general practitioners: Feasibility in Switzerland. 
 
4.7 Childhood cancer and vicinity of residence to petrol stations 
and roads: census-based nationwide cohort study (PETROL) 
Background: Benzene is one of the most common traffic-related air-pollutants; it is 
haematotoxic and an established human carcinogen. Its association with acute myeloid 
leukaemia is well documented in adults but data on children are scarce. To our knowledge, 
no cohort studies have investigated potential associations between benzene exposure and 
childhood cancer in children. 
Objective: To examine whether 1) residence in the proximity of petrol stations, motor 
vehicle service stations or major roads, and 2) parental profession-related exposure to 
benzene is associated with a higher risk of cancer, particularly leukaemia, in children and 
adolescents. 
Methods: The study includes all children born between January 1985 and December 
2008, aged 0-19 years at diagnosis and resident in Switzerland (N=5300). Analyses will 
be based on information obtained from the SCCR, the Swiss National Birth Registry (NBR) 
and the Swiss National Cohort (SNC), a long-term, census-based cohort that includes all 
Swiss inhabitants. All addresses will be geocoded to assess their proximity to petrol stations, 
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motor vehicle service stations and major roads. We will consider place of residence at birth 
and at diagnosis separately. Geographic data on petrol and motor vehicle service stations 
will be obtained from the census of businesses; data on roads from the Tele Atlas database. 
Data on parental occupation during the 1990 and 2000 censuses will be obtained from the 
SNC and will allow us to identify children whose parents were exposed to benzene at work. 
The data will be analysed using Poisson regression models, adjusting for socio-economic 
status, parental age at birth, birth weight and length, birth order and number of siblings. 
Rational and Significance: Traffic-related pollution and its effects on health are a major 
public health issue because a substantial proportion of the population is exposed. This 
unique, large-scale study will help clarify whether traffic-related air pollution has an impact 
on the incidence of childhood cancer in the general population. 
Current status of project: Most of the preparatory work has been completed. We have 
obtained geocoded address of residence at diagnosis (94%) and birth (73%) for most 
eligible cases. Distances to nearest petrol stations, motor vehicle service stations and major 
roads have been calculated and associations with cancer risk are being analysed. We are 
collaborating with the Utrecht University, Holland, to identify occupations with high 
benzene exposure and analyses of these data will begin shortly.  
Applicants: Feller M, Spoerri A. Institute of Social and Preventive Medicine, University of 
Bern; von der Weid NX. Paediatric Oncology, University Children’s Hospital Basel (UKBB); 
Zwahlen M, Egger M, Kuehni CE. Institute of Social and Preventive Medicine, University of 
Bern. 
Project team: Spycher BD, Spoerri A, Zwahlen M, Gueler A, Kuehni CE. Institute of 
Social and Preventive Medicine, University of Bern.  
Funding: Federal Office of Public Health (Grant No 10.002946). 
Contact: Claudia Kuehni (kuehni@ispm.unibe.ch); Ben Spycher (bspycher@ispm.unibe.ch) 
Publications: Expected for 2013. 
 
4.8 Developing a model to predict domestic radon exposure for 
Swiss children 
Background: Radon is associated with lung cancers in adults, but less is known about 
its association with childhood cancers. Most studies published on this issue so far are 
ecological and do not control for confounders, or they are case-control studies with 
inconsistent results and possible recall and selection bias. 
Objectives: To develop a radon exposure model and to predict domestic radon exposure 
for children in Switzerland. To investigate if an elevated indoor radon concentration 
increases risk of childhood cancers, specifically leukaemia and central nervous system (CNS) 
tumours. 
Methods: A prospective census-based cohort design is used to investigate the association 
between radon exposure and childhood cancer. All children aged 0-15 years, born before   
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5 December 2000 (date of census), and resident in Switzerland were included in the cohort. 
Follow-up period lasted until death, emigration or 31 December 2008. The SCCR identified 
eligible cases. About 1,000 childhood cancer cases, including 285 leukaemias (227 with ALL) 
and 258 CNS-tumours were included. The Swiss National Cohort (SNC) provided place of 
residence on the date of census for all children of the cohort, mortality, emigration data for 
the calculation of follow-up time, and information about confounders such as socio-
economic status or number of children in the household. The data was analysed using Cox 
regression adjusting for confounders. To assess individual exposure to radon at the place of 
residency, we developed a model for domestic radon exposure using the radon database of 
the Swiss Federal Office of Public Health and geographically referenced information (e.g. 
building register, geology). The radon database consists of indoor measurements for about 
100,000 buildings in Switzerland. We used 44,631 measurements collected between 1994 
and 2004 for model development (80% of the data) and for model validation (20%). 
Rationale and significance: Selection bias will be minimal because direct contact with 
study participants is unnecessary. Thus, this study overcomes major methodological 
problems found in most previous studies on the topic and will help to reveal whether low 
dose ionizing radiation is associated with a higher risk for childhood cancer. The study will 
also provide new information on the exposure of the Swiss population to radon which is 
preventable but accounts for almost half of the average annual ionizing radiation dose in 
Switzerland.  
Current status of project: We developed the radon prediction model and assessed 
individual exposure to radon at the place of residency using this model. We analysed if 
radon exposure is associated with a higher risk of childhood malignancy using Cox 
regression models. We did not find an association between radon exposure and childhood 
cancer in general, and childhood leukaemia and CNS tumours in particular. 
Applicants: Röösli M. Swiss Tropical and Public Health Institute Basel; Kuehni CE. Institute 
of Social and Preventive Medicine, University of Bern; Huss A. Institute for Risk Assessment 
Sciences, Utrecht University, The Netherlands. 
Project team: Hauri D, Röösli M. Swiss Tropical and Public Health Institute Basel; 
Kuehni CE. Institute of Social and Preventive Medicine, University of Bern; Zimmermann F. 
University Hospital Basel. 
Funding: Swiss National Science Foundation (ProDoc Grant No PDFMP3_124951). 
Contact: Martin Röösli (martin.roosli@unibas.ch) 
Publications (published):  
Hauri DD, Huss A, Zimmermann F, Kuehni CE, Röösli M. A prediction model for assessing 
residential radon concentration in Switzerland, Journal of Environmental Radioactivity 
2012; 112: 83-89. 
Publications (submitted):  
Hauri DD, Huss A, Zimmermann F, Kuehni CE, Röösli M. Nationwide prediction of 
residential radon exposure of the whole Swiss population: comparison of model-based 
with measurement based predictions. 
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4.9 Effectiveness of transition from paediatric to adult care after 
childhood cancer 
Background: Transition from paediatric to adult care is a crucial step in many chronic 
diseases of childhood. Treatments in paediatric oncology have improved over the past 
decades; now about 80% of patients survive to adulthood. However, 60% suffer from 
adverse somatic or psychosocial late effects from the cancer and its treatments and 
necessitate long-term follow-up. Generally, follow-up is well organised during the first 5-10 
years after diagnosis. Often follow-up occurs in the context of a clinical trial. However, 
transfer of patients to adult care often fails and survivors may be lost to follow-up or 
continue to visit their paediatric institution despite their adult status and changing needs.  
Objectives: The project aims to: 1) determine the frequency of follow-up in childhood 
cancer survivors when they are in paediatric care; 2) describe transfer modalities; 3) describe 
the health care providers involved in follow-up and transfer; 4) determine factors associated 
with successful transfer; and 5) describe advantages and disadvantages of different kinds of 
follow-up to survivors, families and health care providers from paediatric and adult wards.  
Method: This study will analyse information collected from medical records on follow-up 
care, transitional care and transfer to adult care. Additional information on current follow-
up, socio-economic characteristics and late effects comes from two separate, on-going 
questionnaire studies (Swiss Childhood Cancer Survivor Study and Childhood Cancer 
Follow-Up Study).  
Rationale and Significance: The available information will be used to develop the first 
national guidelines for the transition of childhood cancer survivors. In addition, results will 
provide a basis for improvement of transitional care for other chronic diseases.  
Current status of project: In the first pilot phase, begun in the second half of 2011, we 
checked medical records to see what information was available and what formats were 
used for archiving the records. Since February 2012 we collected data in six of the nine 
SPOG clinics. Data collection will also be a main focus in 2013.  
Applicants: Michel G, Kuehni CE. Institute of Social and Preventive Medicine, University of 
Bern; von der Weid NX. Paediatric Oncology, University Children’s Hospital Basel (UKBB); 
Bergsträsser E. Paediatric Oncology, University Children’s Hospital Zurich; Ketterer N. 
Paediatric Oncology, CHUV Lausanne. 
Project team: Gianinazzi ME, Michel G, Kuehni CE, Essig S, Rupp E, Brunner I, Wittwer S. 
Institute of Social and Preventive Medicine, University of Bern. Von der Weid NX. Paediatric 
Oncology, University Children’s Hospital Basel (UKBB). Bergstraesser E. Paediatric Oncology, 
University Children’s Hospital Zürich. 
Funding: Swiss Cancer League (Grant No KLS 02631-08-2010).  
Contact: Micol Gianinazzi (mgianinazzi@ispm.unibe.ch), Gisela Michel 
(michel@ispm.unibe.ch) 
Publications: Expected for 2013-2014. 
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4.10 Mortality and second primary cancers after cancer in childhood 
and adolescence 
Background: Despite improved cure rates, all-cause mortality of childhood cancer survivors 
is several times higher than in the general population. In the first 10 years after diagnosis 
recurrence of the primary cancer is the main cause of death, but thereafter deaths from 
second primary cancers predominate. This underlines the need to identify avoidable risk 
factors for these late consequences. 
Objectives: We aim to analyse incidence and risk factors in survivors of childhood and 
adolescent cancer for: 1) total and cause-specific mortality, including late mortality (>5 years 
after diagnosis of cancer) and 2) second primary cancers.  
Methods: The study population for this project consists of all children and adolescents 
registered in the Swiss Childhood Cancer Registry (SCCR). For all participants vital status and 
date of death has been updated via municipal population registers. Cause of death is 
obtained via linkage with the Swiss mortality statistics. Incidence of second primary cancers 
will be assessed via: 1) direct notification from treatment centres; 2) mortality records (for 
deceased); 3) data linkage with cantonal cancer registries and, 4) a questionnaire survey 
among all survivors. Second primary cancers reported in the questionnaire will be validated 
with medical records. In a first analysis we will calculate standardised mortality ratios and 
absolute excess risk of death in the study population compared to expected numbers in the 
general population. Further, we will determine risk factors for total and late mortality and 
for second primary cancers. 
Rationale and significance: This project will provide the first data on long-term mortality 
and second primary cancers after cancer in childhood and adolescence in Switzerland. The 
identification of avoidable risk factors for premature death and second primary cancers will 
allow adapting treatment in new patients, aiming at maximal cure rates with minimal long-
term side effects.  
Current status of project: We confirmed vital status or date of death via municipal 
population registers, and obtained cause of death from Swiss mortality statistics. By 
December 2012 we identified 2196 patients who died in the first 5 years after diagnosis. 
Additionally, we identified 351 patients who died more than 5 years after diagnosis. Cause 
of death is available for 95% of patients deceased. Linkage with cantonal registries to 
detect second primary neoplasms is still in process.  
Applicants: Kuehni CE, Michel G, Egger M, Institute of Social and Preventive Medicine 
(ISPM) University of Bern. 
Project team: Schindler M, Kuehni CE, Michel G, Hau E, Mitter V. Institute of Social and 
Preventive Medicine, University of Bern, Ammann RA, University Children’s Hospital, 
Inselspital Bern. 
Funding: Swiss National Science Foundation (ProDoc Grant No PDFMP3_141775), Swiss 
Bridge Foundation 
Contact: Claudia Kuehni (kuehni@ispm.unibe.ch) 
Publications: Expected for 2014-2015. 
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4.11 Childhood cancer and geographically defined exposures in 
Switzerland: a census-based nationwide cohort study 
Background: Ionising radiation is the only environmental exposure that has been clearly 
linked to cancer in children. It is, however, still unclear whether the dose-response 
relationships found in studies of persons exposed to moderate or high doses can be 
extrapolated to the lower doses from background radiation. In Switzerland, exposure to 
cosmic radiation has a relatively high variation because of differences in altitude between 
residential locations.  
Objective: To examine the risk of cancer in children and adolescents associated with 
exposure to background ionising radiation from cosmic, terrestrial and artificial sources. 
Methods: The study includes all children born between January 1985 and December 
2008, aged 0-19 years at diagnosis and resident in Switzerland (N=5300). Analyses will 
be based on information obtained from the SCCR and the Swiss National Cohort (SNC), 
a long-term, census-based cohort that includes all Swiss inhabitants. We will compute 
dose rates of ionising radiation (unit: nSv/h) at address of residence at diagnosis and at birth 
for all cancer cases and for all individuals in the SNC aged <20 years. We will consider 
prenatal (conception to birth) and postnatal (birth to diagnosis) cumulative exposures. In a 
first analysis (aggregate data analysis), we will compare incidence rates for cancer and 
leukaemia across exposure categories using Poisson regression, adjusting for potential 
confounders. In a second step (individual data analysis) we will analyse individual time-to-
event data based on record linkage between the SCCR and the SNC using Cox-proportional 
hazard models. 
Current status of project: The study has just begun (Nov 2012-Nov 2013).  
Applicants: Kuehni CE, Spycher BD. Institute of Social and Preventive Medicine, University 
of Bern. 
Project team: Spycher BD, Lupatsch J, Kuehni CE. Institute of Social and Preventive 
Medicine, University of Bern.  
Funding: Federal Office of Public Health (Grant No 12.008357). 
Contact: Ben Spycher (spycher@ispm.unibe.ch), Claudia Kuehni (kuehni@ispm.unibe.ch) 
Publications: Expected for 2013-2014 
 
4.12 The role of population mixing and exposure to infections in the 
aetiology of childhood leukaemia: a national cohort study 
Background: Leukaemia is the most important cancer among children in industrialized 
countries. Infections may play a role: the incidence of acute lymphocytic leukaemia (ALL) is 
higher in resource-rich countries, where infections early in life are less common compared to 
resource-poor settings; there is a sharp peak in incidence at 2-5 years of age; local clusters 
of cases have been described and there is seasonal variation in the diagnosis of ALL. Kinlen 
proposed that population mixing, i.e. large influxes of people into previously isolated areas, 
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could explain clusters of childhood leukaemia. Childhood leukaemia may thus be a rare 
response to a common, yet unidentified, infection. Greaves proposed the delayed-immune 
hypothesis as an explanation for the peak incidence of ALL at 2-5 years: a lack of exposure 
to infections in early life could predispose the immune system to aberrant responses to 
subsequent ‘delayed’ infections. 
Aims: To determine whether leukaemia (any leukaemia and ALL) diagnosed <20 years of 
age is associated with the following measures of population mixing at community level 
(Kinlen’s hypothesis): 1) Volume and diversity of in-migration into communities, and 2) 
Change in annual in-migration; or with proxy measures of exposure to infections (Greaves’ 
hypothesis): 3) Birth order, 4) Child density in neighbourhood, and 5) Extra-familial child-
care. 
Methods: The study will use data from the Swiss National Cohort (SNC), the Swiss 
Childhood Cancer Registry (SCCR), the childhood cancer cytogenetic database (CCD) and 
demographic data from the Swiss Federal Statistical Office. Primary outcomes will be any 
leukaemia and ALL in particular. Secondary outcomes will be the most prevalent 
immunophenotype, B-cell-precursor ALL, and cytogenetic subgroups like high hyperdiploidy 
and TEL1-AML1 translocation. Geocodes of both addresses at birth and at diagnosis will be 
analysed. Exposures will include percentage of population that moved into a community 
over 5-year periods, diversity of areas of origin (Shannon’s entropy), change in annual in-
migration volume relative to average in-migration in previous years, the rank of the child 
among all live births of the same mother, neighbourhood indices of child density developed 
using road network connectivity, and parental full-time employment as a proxy measure of 
extra-familial child-care. We will estimate and compare incidence across quintiles of 
exposure measures using Poisson regression (analyses of aggregated data) and Cox 
regression (individual data). Analyses will be adjusted for age, sex and calendar year and, in 
a second step, for other potential confounders. 
Significance: The possibility that childhood leukaemia might be associated with a specific 
infection or with later exposure to infections is highly relevant for prevention. Previous 
studies were limited by the lack of spatial or temporal precision and few studies were able 
to use both residential locations at birth and at diagnosis. Many were case-control studies 
and at risk of selection bias and recall bias. In the present study only routine data bases with 
national coverage will be used and precise geocoding of both address at birth and diagnosis 
will allow high temporal and spatial resolution. 
Current status of project: The study begins in January 2013.  
Applicants: Spycher BD, Egger M and Kuehni CE, Institute of Social and Preventive 
Medicine, University of Bern; Ammann RA, University Children’s Hospital, Inselspital Bern; 
Niggli F, University Children’s Hospital, Zurich. 
Project team: Spycher BD, Lupatsch J, Kuehni CE. Institute of Social and Preventive 
Medicine, University of Bern; Ammann RA, University Children’s Hospital, Inselspital Bern. 
Funding: Cancer Research Switzerland (Grant No KFS 3049-08-2012). 
Contact: Ben Spycher (bspycher@ispm.unibe.ch) 
Publications: Expected for 2014-2015 
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5. Publications  
All articles published using SCCR data from January 2006 – December 2012 are reported 
below. Additional publications related to the SCCR or SPOG can be found on the SCCR and 
SPOG websites: www.childhoodcancerregistry.ch and www.spog.ch. 
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6. Abbreviations 
ALL Acute Lymphoblastic Leukaemia 
AML Acute Myeloid Leukaemia 
CANUPIS Childhood Cancer and Nuclear Power Plants in Switzerland 
CCFU Childhood Cancer Follow-up study 
CHUV Centre Hospitalier Universitaire Vaudois 
CNS Central Nervous System 
DNA Deoxyribonucleic Acid 
ENCR European Network of Cancer Registries 
FOPH Federal Office of Public Health 
GCCR German Childhood Cancer Registry, Mainz, Germany 
GH Growth Hormone 
GHD Growth Hormone Deficiency 
GIS Geographic Information System 
HUG Hôpitaux Universitaires de Genève 
HRQoL Health Related Quality of Life 
IACR International Association of Cancer Registries 
IARC International Agency for Research on Cancer 
ICCC-3 International Classification of Childhood Cancer, Third revision 
ICD-10 International Statistical Classification of Diseases and Related Health 
Problems, Tenth revision 
ICD-O-3 International Statistical Classification of Diseases for Oncology, Third 
edition 
IRR Incidence Rate Ratio 
ISPM Institute of Social and Preventive Medicine, Bern 
LCH Langerhans Cell Histiocytosis 
MD Medical Doctor 
MSc Master of Science 
NBR National Birth Registry 
NICER National Institute for Cancer Epidemiology and Registration, Zurich 
NPP Nuclear Power Plants 
nSv/h Nano Sievert per Hour  
PanCare Pan-European Network for Care of Survivors after Childhood and 
Adolescent Cancers 
PanCareSurFup PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up 
Studies 
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Abbreviations - continued 
 
PD Privatdozent 
PhD Doctor of Philosophy 
RF Radio Frequency 
SAGhE Safety and Appropriateness of Growth Hormone Treatment in Europe 
SCCR Swiss Childhood Cancer Registry 
SCCSS Swiss Childhood Cancer Survivor Study 
SFSO Swiss Federal Statistical Office 
SNC Swiss National Cohort 
SPOG Swiss Paediatric Oncology Group 
STS Soft Tissue Sarcoma 
UKBB Universitätskinderspital beider Basel 
WHO World Health Organization 
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7. Appendix: Classification of cancer diagnoses  
International Classification of Childhood Cancer - ICCC-3 
The third edition of the International Classification of Childhood Cancer (ICCC-3) represents the 
standard for presentation of international data on childhood cancer incidence and survival.5 It applies 
the rules, nomenclature and codes (morphology, topography and behaviour) of the ICD-O-3. 
Furthermore, ICCC-3 categories are defined in conformity with international classifications of the 
pathology and genetics of childhood cancers. In the ICCC-3, three hierarchical levels have been 
developed: level one consists of 12 main diagnostic groups and level two of 47 diagnostic subgroups. 
These two levels of the ICCC-3 allow standardised comparison of the broad categories of childhood 
tumours. Level three, an optional “extended” classification, comprises two to eleven divisions of 
selected diagnostic subgroups. The division of some diagnostic subgroups, e.g. leukaemias and Non-
Hodgkin lymphomas, reflects the availability of detailed cytogenetic or molecular information that 
permits homogeneous groups of tumours to be distinguished within them and thus allows their 
separate study. The Swiss childhood cancer registry uses level one to three. Only malignant 
neoplasms are classified in ICCC-3, with the exception of non-malignant intracranial and intraspinal 
tumours. Tumours known to occur only rarely in young patients are also included in ICCC-3. The 
ICCC-3 is used if data are compared with other childhood cancer registries. 
International Statistical Classification of Diseases for Oncology - ICD-O-3 
The third edition of the International Statistical Classification of Diseases for Oncology (ICD-O-3)6 has 
been developed by a working group hosted by the International Association of Research in Cancer 
(IARC) and WHO. The morphology code for neoplasm has been revised, especially for lymphomas 
and leukaemias. In contrast to the ICD-10 classification, ICD-O-3 uses only one set of four characters 
for topography (based on the malignant neoplasm section of ICD-10). The topography code remains 
the same for all neoplasms of that site. The behaviour code is incorporated as the fifth digit in the 
morphology field. It identifies whether the tumour is malignant, benign, of uncertain or unknown 
behaviour, in situ, presumed to be primary or secondary. ICD-O-3 is used to compare data with 
general cancer registries. 
International Statistical Classification of Diseases and Related Health Problems - 
ICD-10 
The International Statistical Classification of Diseases and Related Health Problems (ICD)7 permits the 
systematic recording, analysis, interpretation and comparison of mortality and morbidity data 
collected in different regions and at different time periods. The ICD has become the international 
standard diagnostic classification for all general epidemiological purposes. The ICD-10 classification 
comprises three volumes: Volume 1 contains the main classifications; Volume 2 provides guidance for 
users of the ICD; and Volume 3 is the alphabetical index to the classification. Classification is divided 
into 21 chapters. The first character of the ICD code is a letter. Each letter is associated with a 
particular chapter, e.g. the letter D is used in both chapter II “Neoplasms” and chapter III “Diseases 
of the blood and blood-forming organs and certain disorders involving the immune mechanism”. The 
topography code in Volume 3 describes the site and the behaviour of the neoplasm: malignant, 
secondary or metastatic, in situ, benign or of unknown behaviour. The morphology codes listed in 
Volume 1 are the same as those used in the special adaptation of the ICD for oncology, the ICD-O67.. 
                                               
5 Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer 2005; 103:1457-67. 
6 World Health Organization. International Statistical Classification of Diseases for Oncology - Third Edition (ICD-O-3). Geneva: World Health Organization; 2000. 
7 World Health Organization. International Statistical Classification of Diseases and Related Health Problems - Tenth Revision. Geneva: World Health Organization; 1993. 

